Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ADO-TRASTUZUMAB EMTANSINE Cause Epistaxis? 327 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 327 reports of Epistaxis have been filed in association with ADO-TRASTUZUMAB EMTANSINE. This represents 3.8% of all adverse event reports for ADO-TRASTUZUMAB EMTANSINE.

327
Reports of Epistaxis with ADO-TRASTUZUMAB EMTANSINE
3.8%
of all ADO-TRASTUZUMAB EMTANSINE reports
19
Deaths
91
Hospitalizations

How Dangerous Is Epistaxis From ADO-TRASTUZUMAB EMTANSINE?

Of the 327 reports, 19 (5.8%) resulted in death, 91 (27.8%) required hospitalization, and 12 (3.7%) were considered life-threatening.

Is Epistaxis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ADO-TRASTUZUMAB EMTANSINE. However, 327 reports have been filed with the FAERS database.

What Other Side Effects Does ADO-TRASTUZUMAB EMTANSINE Cause?

Nausea (780) Fatigue (774) Disease progression (750) Diarrhoea (654) Off label use (630) Thrombocytopenia (519) Death (509) Neuropathy peripheral (506) Headache (465) Platelet count decreased (453)

What Other Drugs Cause Epistaxis?

RIVAROXABAN (5,629) ASPIRIN (3,214) APIXABAN (2,831) FLUTICASONE (1,745) TREPROSTINIL (1,726) CLOPIDOGREL BISULFATE (1,560) BEVACIZUMAB (1,542) WARFARIN (1,498) PALBOCICLIB (1,280) ADALIMUMAB (1,243)

Which ADO-TRASTUZUMAB EMTANSINE Alternatives Have Lower Epistaxis Risk?

ADO-TRASTUZUMAB EMTANSINE vs ADRIAMYCIN ADO-TRASTUZUMAB EMTANSINE vs ADUCANUMAB ADO-TRASTUZUMAB EMTANSINE vs ADUCANUMAB-AVWA ADO-TRASTUZUMAB EMTANSINE vs ADVAIR ADO-TRASTUZUMAB EMTANSINE vs ADVAIR HFA

Related Pages

ADO-TRASTUZUMAB EMTANSINE Full Profile All Epistaxis Reports All Drugs Causing Epistaxis ADO-TRASTUZUMAB EMTANSINE Demographics